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Abstract: A major problem in treating cancer is the development of drug resistance. We 
previously demonstrated doxorubicin (DOX) resistance in K562 human leukemia cells that 
was associated with upregulation of glyoxalase 1 (GLO-1) and histone H3 expression. The 
thiazolidinedione troglitazone (TRG) downregulated GLO-1 expression and further upregulated 
histone H3 expression and post-translational modiﬁ  cations in these cells, leading to a regained 
sensitivity to DOX. Given the pleiotropic effects of epigenetic changes in cancer development, 
we hypothesized that TRG may downregulate the multiple drug resistance (MDR) phenotype 
in a variety of cancer cells. To test this, MCF7 human breast cancer cells and K562 cells were 
cultured in the presence of low-dose DOX to establish DOX-resistant cell lines (K562/DOX 
and MCF7/DOX). The MDR phenotype was conﬁ  rmed by Western blot analysis of the 170 kDa 
P-glycoprotein (Pgp) drug efﬂ  ux pump multiple drug resistance protein 1 (MDR-1), and the 
breast cancer resistance protein (BCRP). TRG markedly decreased expression of both MDR-1 
and BCRP in these cells, resulting in sensitivity to DOX. Silencing of MDR-1 expression 
also sensitized MCF7/DOX cells to DOX. Use of the speciﬁ  c and irreversible peroxisome 
proliferator-activated receptor gamma (PPARγ) inhibitor GW9662 in the nanomolar range not 
only demonstrated that the action of TRG on MCF/DOX was PPARγ-independent, but indicated 
that PPARγ may play a role in the MDR phenotype, which is antagonized by TRG. We conclude 
that TRG is potentially a useful adjunct therapy in chemoresistant cancers.
Keywords: chemotherapy, doxorubicin, breast cancer resistance protein-1, multiple drug 
resistance, multiple drug resistance protein 1
Introduction
Chemotherapy is an important tool in both the initial treatment of many cancers,1 as well 
as in treating metastatic cancer.2 However, a large proportion of patients either do not 
respond to chemotherapy or lose their initial responsiveness.2 Breast cancer is a major 
worldwide health issue for women, and has often already metastasized by the time of 
initial diagnosis.3 Every year, 1,000,000 new cases are diagnosed, with 40,000 deaths 
in the United States alone every year. The response rates of metastatic breast cancer to 
initial treatment ranges from 30%–70%, and is frequently temporary, as time to disease 
progression following these treatments is only 6–10 months. The response rate for second 
round chemotherapy for those whose disease progresses falls to 20%–30% with a median 
duration of response less than six months. This failure to respond to chemotherapy is 
primarily due to drug resistance mechanisms. The most common mechanism of drug 
resistance is expression of the drug efﬂ  ux pumps belonging to the adenosine triphos-
phate (ATP)-binding cassette (ABC) transporter family.2 One of the most commonly 
expressed of these transporters is the multiple drug resistance protein 1 (MDR-1; or 
ABCB1) gene that encodes for P-glycoprotein (Pgp). For example, approximately 50% 
of all breast cancers have been reported to express the MDR-1 gene4 and resistance to 
chemotherapy correlates with MDR-1 expression.5,6 There is now a concerted effort to 
develop drugs that can overcome multiple drug resistance (MDR).7,8Drug Design, Development and Therapy 2009:3 80
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We had previously shown that the peroxisome-proliferator 
activated receptor gamma (PPARγ) agonist troglitazone 
(TRG), but not other thiazolidinediones, downregulated 
glyoxalase I gene expression in a variety of cell types.9 
Since overexpression of glyoxalase I is present in a 
number of cancers, increased expression of glyoxalase I 
is thought to contribute to drug resistance.10,11 We had 
hypothesized that TRG would be capable of downregu-
lating glyoxalase I gene expression in tumor cells and 
sensitize these cells to therapeutic intervention. Indeed, 
our subsequent experiments did show that TRG downregu-
lated glyoxalase I and did overcome doxorubicin (DOX) 
resistance in DOX-resistant K562 human leukemia cells.12 
These results led us to hypothesize that TRG may also 
downregulate MDR-1 gene expression in cancer cells. 
Here, we present data that TRG does indeed downregulate 
increased expression of MDR-1 in DOX-resistant K562 
leukemia cells and MCF7 human breast cancer. Our results 
suggest TRG may be a useful adjunct therapy in treating a 
variety of cancer cells.
Materials and methods
Cell culture
MCF7 human breast cancer cells, as well as K562 human leu-
kemia cells (obtained from American Type Culture Collection), 
were cultured in 75 cm2 tissue culture ﬂ  asks (Falcon) in 
Dulbecco’s Modiﬁ  ed Eagle’s Medium (DMEM-F12) and 
RPMI 1640 media, respectively, containing 10% fetal bovine 
serum (Invitrogen, Carlsbad, CA, USA). Cells were cultured in 
a humidiﬁ  ed atmosphere (5% CO2) at 37 °C and at appropriate 
times were incubated for 48 h in the presence of the compounds 
at the indicated concentrations.
DOX-resistant cell selection
Parental MCF7 and K562 cells were cultured in the presence 
of 1 μM DOX over a period of 72 h. At the end of this period 
the cells were washed with sterile phosphate-buffered saline 
(PBS) to remove the DOX and fresh DOX-free growth 
medium was added. Following a month-long recovery period 
(with fresh medium changes every 3 days) 1 μM DOX was 
again added to the cells for 72 h. Following a PBS wash 
10 nM DOX was added to the medium to maintain selec-
tion pressure. These selected mutant lines were designated 
MCF7/DOX and K562/DOX, respectively. Selected cells 
were washed free of any DOX prior to experimentation. 
Selected MCF7/DOX maintained their MDR phenotype 
after long-term storage in liquid nitrogen without requiring 
re-selection.
Cultures were treated with one of the following: 1 μM 
DOX, 50 or 100 μM TRG, 1 μM DOX plus 50 μM TRG 
or simply the dimethylsulfoxide vehicle (DMSO: final 
concentration of 0.1%) in which DOX and TRG was 
prepared.
Western blot analysis
Breast cancer cells were removed from the culture dishes 
using a rubber policeman and ice-cold lysis buffer. K562 
cells, which were either loosely adherent or ﬂ  oating, were 
removed in their medium, centrifuged at 300 × g and 
resuspended in ice-cold lysis buffer. The composition of 
the lysis buffer was as follows: 20 mM HEPES (pH 7.5), 
50 mM KCl, 10% glycerol, 0.5 mM EDTA, 0.1 mM EGTA, 
1mM DTT plus 1 × mammalian cell anti-protease cocktail 
(Sigma Aldrich Canada, Oakville, ON, Canada). The cells 
were lysed using multiple freeze-thaw cycles followed by 
pulse sonication and centrifugation at 300 × g to remove 
nonlysed cell debris. For Western blot analysis, equivalent 
amounts of protein (assessed by Bradford protein assay13 
using BioRad Protein Reagent; BioRad Laboratories, 
Hercules, CA, USA) were resolved by sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). 
Following electrophoresis the proteins were trans-
blotted onto nitrocellulose membranes (Pall-VWR). The 
membranes were blocked with 5% molecular grade fat free 
skim milk powder (BioRad Laboratories) in phosphate-
buffered saline (PBS) containing 0.1% Tween-20 (PBST). 
Primary and secondary antibody incubations and subse-
quent washes were carried out in the same buffer. Sec-
ondary horseradish peroxidase (HRP) antibodies were 
purchased from BioRad Laboratories. Blots were blocked 
overnight at 4 °C on a gyratory plate and probed with pri-
mary antibodies at a 1:1000 dilution overnight. Secondary 
HRP antibody was applied at room temperature on a gyra-
tory plate at a concentration of 1:10,000 for 30 min. Fol-
lowing washes, an enhanced chemiluminescence detection 
system (DuPont-NEN®; DuPont, Boston, MA, USA) was 
used to detect the antigen/antibody complexes. Blots were 
then stripped and reprobed for either actin, α-tubulin or 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 
protein load controls. Alternatively, Coomassie-stained 
gels were shown as load controls. Primary antibodies 
to alpha-tubulin and actin were obtained from Sigma 
Aldrich and Pgp antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Antibody to breast 
cancer resistance protein 1 (BCRP1) was obtained from 
Abcam (Cambridge, MA, USA).Drug Design, Development and Therapy 2009:3 81
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MTT cell viability assay
Determination of cell viability was accomplished by the 
MTT assay. The MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay is a colorimet-
ric method that is widely used to determine viability of 
eukaryotic cells following drug treatment.14 This assay is 
based upon the reduction of MTT (a yellow compound) 
to a purple formazan in the mitochondria of living, viable 
cells. Cancer cell suspensions were prepared at a concen-
tration of approximately 106 cells per ml as determined by 
standard hemocytometry and cultured in six-well multiwell 
plates. These cultures were treated simultaneously with cells 
cultured in 75 cm2 tissue culture ﬂ  asks dedicated to protein 
extraction and Western blot analysis. For MTT analysis cells 
were cultured in phenol red-free medium to avoid interfer-
ing with the colorimetric analysis of the purple formazen 
MTT product. Following 48 h of treatment cells were treated 
with MTT followed by washing, dodecyl sulfate (SDS) 
solubilization of the formazan product and spectrometric 
analysis at 570 nm.
RNA silencing
MCF7/DOX cells (106) were transfected with 1 μg of duplex 
human MDR-1 small interfering RNA (siRNA) following 
the manufacturers instructions (Santa-Cruz Biotechnology). 
Briefly, cells were cultured in 100 mm tissue culture 
plates and washed with PBS, followed by serum-free and 
antibiotic-free DMEM prior to transfection. siRNA duplex 
solutions (fluorescein-conjugated, scrambled siRNA 
control and MDR-1 siRNAs) were prepared by adding 1 μg 
(80 pmols) of MDR-1 siRNA to the supplied transfection 
reagent (sc-29528). The resulting reaction mixture was 
allowed to complex for 30 minutes at room temperature. 
Next, the mixture was gently overlayed onto the cells, and 
incubated for six hours at 37 °C in a CO2 incubator. Following 
this incubation period, an equivalent volume of 2 × growth 
media (20% fetal bovine serum [FBS] and 2 × antibiotics) 
was added without removing the transfection mixture, and the 
cells were incubated overnight. The next morning the cells 
were washed once with phosphate-buffer solution (PBS) and 
resuspended in 1 × growth media. Incubation of the siRNA 
transfected cells was continued and analysis was performed 
after 72 h. Fluorescein conjugated scrambled control siRNA 
treated cells were quantiﬁ  ed using ﬂ  uorescence microscopy 
(Olympus, Lehigh Valley, PA) to determine transfection 
efﬁ  ciency and whole cell lysates of both scrambled and 
MDR-1 siRNA-treated cells were prepared for MDR-1 
Western analysis.
Reagents
TRG was purchased from Biomol Laboratories (Plymouth 
Meeting, PA, USA). DMEM-F12 media was purchased from 
Sigma Aldrich Canada. Fetal bovine serum and antibiotics 
were purchased from Invitrogen. Molecular biology grade 
skim milk powder was purchased from BioRad Laboratories 
Canada (Mississauga, ON) while DOX and all other reagents 
were purchased from Sigma Aldrich Canada.
Statistical analysis
Data from one cell type were examined with a one-way 
ANOVA and post-hoc Tukey–Kramer Multiple Com-
parisons test. Data between specific cell types of any 
given treatment were examined with the nonparametric 
Mann–Whitney test.
Results
Unselected MCF7 cells expressed a low basal level of the 
ATP-transporters MDR-1 and BCRP (Figure 1A). DOX 
selection resulted in elevated MDR-1 and BCRP signals in 
MCF7 cells. Next, we tested whether treatment of DOX-
selected cells with TRG would decrease expression of 
MDR-1 and BCRP. As with the GLO-1 downregulation we 
observed earlier,12 50 μM TRG downregulated MDR-1 in 
MCF7 cells (Figure 1A). For BCRP downregulation, 100 μM 
TRG was required rather than 50 μM TRG for MDR-1 down-
regulation. We also observed downregulation of MDR-1 
and BCRP by 50 μM TRG in F98 rat glioblastoma cells and 
H411E rat hepatoma cells (data not shown). Use of TRG 
at 50–100 μM is well above the half maximal inhibitory 
concentration (IC50) of TRG for PPARγ which is 0.42 μM 
in rat adipocytes and 1.05 μM in human adipocytes.15 None-
theless, primary hepatocytes easily tolerate doses as high as 
200 μM TRG.16
Similar results were observed with K562 cells, as DOX 
selection dramatically increased MDR-1 protein levels 
(Figure 1B). Downregulation of MDR-1 in K562/DOX 
cells was speciﬁ  c to TRG, as rosiglitazone (ROSI) and pio-
glitazone (PIO) had no effect (Figure 1C). Interestingly, we 
could not detect BCRP expression in K562 cells regardless 
of whether the cells were selected or not (Figure 1D).
We recently discovered that TRG harbors histone 
deacetylase inhibitor activity (Davies and Harkness, unpub-
lished data). To test whether TRG’s downregulation of the 
ABC transporters could involve epigenetic changes, we 
asked whether another chromatin modiﬁ  er, 5-azacytidine 
(5-AzaC), a DNA methylase inhibitor, could reduce MDR-1 
and/or BCRP expression. Our results clearly demonstrate Drug Design, Development and Therapy 2009:3 82
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Figure 1 Troglitazone (TRG) and 5-azacytidine (5-AzaC) downregulate MDR-1 and BCRP expression levels in doxorubicin (DOX)-resistant MCF7 breast cancer cells. 
A) Representative Western blots analyzing MDR-1 and BCRP protein levels in lysates (100 μg/lane for MDR-1 and 60 μg/lane for BCRP) of unselected and DOX-selected MCF7 
cells. MCF7/DOX cells were treated with 50 or 100 μM TRG for 48 h prior to harvest. For determining the equivalency of the protein load the same Western blot membrane 
was stripped and reprobed with a GAPDH antibody. B) Parental K562 leukemia cells and K562 cells selected for DOX resistance were treated with 50 μM TRG for 48 h. Protein 
lysates were examined for MDR-1 protein expression using Western blotting. Antibodies against α-actin were used to determine equivalency of protein load. C) K562/DOX 
cells were treated with 50 μM ROSI, PIO, or TRG for 48 h prior to cell harvest and protein lysate preparation. Unselected K562 cells and K562/DOX cells treated with the 
drug vehicle DMSO were used as controls. Lysates were analyzed with antibody against MDR-1 or α-actin as a protein load control. D) Protein lysates prepared from selected 
and unselected MCF7 and K562 cells were examined for BCRP expression using antibodies against BCRP. E) Parental MCF7 cells and MCF7/DOX cells were treated with the 
5-AzaC concentrations shown for 48 h. Protein lysates were examined for MDR-1 and BCRP expression using Western blot analyses. Antibodies against GAPDH served as protein 
load controls. F) Graph depicting how TRG (50 μM) and DOX (1 μM) alone or in combination affect the viability of unselected (n = 5/group) and DOX-selected (n = 10/group) 
MCF7 cells. Statistical analyses were done on the different treatments within a group using an ANOVA with a post-hoc Tukey–Kramer multiple comparison tests. Asterisks 
indicate signiﬁ  cant differences (*P  0.05; **P  0.01; ***P  0.001) from the respective control cells. Daggers indicate signiﬁ  cant differences (††P  0.01; †††P  0.001) from 
the respective TRG-treated cells. Double daggers indicate signiﬁ  cant differences (‡‡‡P  0.001) from the respective DOX-treated cells. Statistical analyses between the same 
treatment groups in the unselected and selected cells were done using a nonparametric two-tailed Mann–Whitney test. There is a signiﬁ  cant difference in response of unselected 
cells to DOX compared to selected cells (a. P = 0.008) and in response of unselected cells to DOX plus TRG compared to selected cells (b. P = 0.0007).
Abbreviations: BCRP, breast cancer resistance protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MDR, multiple drug resistance; MDR-1, multiple drug resistance 
protein 1.Drug Design, Development and Therapy 2009:3 83
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that 5-AzaC downregulated both MDR-1 and BCRP in a 
dose-dependent manner in MCF7/DOX cells (Figure 1C). 
Thus, downregulation of MDR-1 and BCRP in MCF7/DOX 
cells likely involves epigenetic changes, potentially within 
the promoters of these genes.
We had previously shown that TRG treatment of K562/
DOX cells resulted in restoration of sensitivity to DOX 
treatment.12 Hence, we asked whether downregulation of 
MDR-1 by TRG in MCF7/DOX cells correlated with resto-
ration of DOX sensitivity. Before addressing this question 
we examined the response of unselected MCF7 cells to 
TRG, DOX and DOX plus TRG. All treatments (for a 48 h 
period) signiﬁ  cantly increased cell death (Figure 1D). TRG 
at 50 μM caused 30% of the cells to die (P  0.01), DOX 
at 1 μM caused 53% of the cells to die (P  0.001) while 
TRG plus DOX caused 63% of the cells to die (P  0.001). 
In DOX-selected cells the addition of TRG (50 μM) for a 
48 h period resulted in a signiﬁ  cant 40% (P  0.05) decrease 
in cell viability (Figure 1D). Although the addition of DOX 
(1 μM) resulted in a decrease in cell viability, this was not 
signiﬁ  cantly (P  0.05) different from the cultures treated 
with only the DMSO vehicle. Treating the DOX-selected 
cultures with both TRG (50 μM) and DOX (1 μM) resulted 
in a loss of 96% of the cells which is signiﬁ  cantly different 
from the control cells (P  0.001), the cells treated only 
with TRG (P  0.001) and cells treated only with DOX 
(P  0.001).
To test whether TRG-dependent downregulation of 
MDR-1 is responsible for resensitizing MCF7/DOX cells 
to DOX, we treated MCF7/DOX cells with MDR-1 siRNA 
oligos. Our results show that MDR-1 siRNA does indeed 
reduce MDR-1 protein expression compared to cells treated 
with MDR-1 scrambled control oligos (Figure 2A). Next, 
MCF7/DOX cells treated with MDR-1 or scrambled siRNA 
oligos were treated with DOX for 48 h, followed by MTT 
analysis to determine cell killing. The only signiﬁ  cant kill-
ing of MCF7/DOX cells was observed with MDR-1 siRNA 
treament followed by DOX exposure (Figure 2B). These 
results suggest that reduction of MDR-1 alone is sufﬁ  cient to 
render MCF7/DOX sensitive to DOX. TRG + DOX treatment 
had a greater effect on MCF/DOX cells than siRNA + 
DOX, perhaps due to its broader range of ABC transporter 
downregulation as well as greater downregulation of MDR-1 
(see Figure 1A).
TRG is a known PPARγ agonist.17,18 However, many 
recent reports demonstrate that TRG has PPARγ-independent 
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Figure 2 MDR-1 gene silencing reduces MDR-1 proteins levels and renders MCF7/DOX cells sensitive to DOX. A) MCF7/DOX cells were treated with MDR-1 or scrambled 
siRNA oligos for 48 hrs. Protein lysates were prepared and analyzed using antibodies against MDR-1 and GAPDH as a protein load control. B) Cell killing was determined by 
MTT analysis of MCF7/DOX cells treated as above. The analysis was repeated three times and standard error of the mean is shown.   A statistical analysis was performed using 
ANOVA with a post-hoc Tukey–Kramer test. MDR-1 siRNA + DOX is signiﬁ  cantly different from control (P  0.5).
Abbreviations: ANOVA, analysis of variance; DOX, doxorubicin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MDR-1, multiple drug resistance protein 1.Drug Design, Development and Therapy 2009:3 84
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activity by acting on uncharacterized off-targets.19,20 To 
examine whether TRG activity in MCF7 cells is PPARγ-
dependent, we exposed TRG-treated MCF7 parental cells 
to increasing doses of the PPARγ irreversible inhibitor 
GW9662. GW9662 inhibits PPARγ with an IC50 of 3.3 nM.21 
We tested the ability of GW9662 to block induction of histone 
H3 lysine 9 (H3K9) acetylation by TRG in parental MCF7 
cells, which we demonstrated in K562 cells12 and have since 
reproduced in multiple cell lines, including MCF7 cells (data 
not shown). We expected that if induction of H3K9 acety-
lation by TRG was PPARγ-dependent, then inhibition of 
PPARγ using GW9662 should abolish this effect. Opposed 
to this prediction, GW9662 increased H3K9 acetylation in 
TRG-treated cells in a dose dependent manner beyond that 
observed with TRG (Figure 3A). This synergistic response 
suggests the novel hypothesis that PPARγ inhibition actually 
enhances TRG activities. Interestingly, GW9662 also induced 
H3K79 methylation in MCF7 cells (Figure 3B), which we 
have observed with TRG treatment (Davies and Harkness, 
unpublished data). Methylation of H3K79 is associated with 
DNA damage,22,23 indicating that PPARγ may promote the 
health of MCF7/DOX cells and act counter to TRG.
To examine whether PPARγ antagonizes TRG action 
on BCRP expression in MCF7/DOX cells, we treated 
selected MCF7 cells with increasing doses of GW9662 and 
asked what effect this had on BCRP expression. Our results 
show that GW9662 alone could reduce BCRP expres-
sion (Figure 3C). Our results provide evidence that TRG 
and PPARγ may have an antagonistic interaction in MCF7 
drug-resistant cells, perhaps by acting in opposite manner 
on MDR-1 expression.
Lastly, we tested whether down regulation of BCRP 
required distinct signaling pathways. We recently observed 
that induction of histone modiﬁ  cations by TRG and the 
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Figure 3 PPARγ inhibition accentuates TRG phenotypes in MCF7 cells. A) MCF7 parental cells were treated with 50 μM TRG or left untreated. To the TRG-treated cells, an 
increasing dose of GW9662 was added, as shown. The cells were incubated with the drugs for 48 h. Protein lysates were then prepared, separated by SDS PAGE and analyzed 
with antibody that speciﬁ  cally recognized acetylated histone H3 Lys9.   A Coomassie Blue (CB)-stained gel is shown as a protein load control. B) Parental unselected MCF7 
cells were treated with the same titration of GW9662 as shown in A. TRG was not used in this experiment. Protein lysates were examined with an antibody that speciﬁ  cally 
recognizes monomethylated histone H3 Lys79, a marker of DNA damage, that is also induced by TRG. Antibody against actin was used as protein load control. C) MCF7/DOX 
cells were treated with the GW9662 dose used above. Unselected control MCF7 cells were used as a control. Lysates were examined with antibodies against BCRP and 
α-tubulin as a protein load control. D) Inhibition of AKT signaling downregulates BCRP expression. MCF7/DOX cells were treated with drugs that inhibit PI3K/AKT signaling, 
LY294002, or ERK signaling, PD98059, for 48 hours. Protein lysates were prepared and analyzed with antibody against BCRP.
Abbreviations: BCRP, breast cancer resistance protein; DOX, doxorubicin; SDS PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; TRG, troglitazone.Drug Design, Development and Therapy 2009:3 85
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histone acetyltransferases trichostatin A (TSA) and PXD101 
depended on AKT inhibition (Davies and Harkness, 
unpublished data). Thus, we predicted that inhibition of AKT 
signaling, using the drug LY294002, would also downregu-
late BCRP expression. Our results conﬁ  rm this prediction, 
as inhibition of AKT signaling reduced BCRP protein levels, 
but inhibition of ERK signaling, using PD98059, did not 
(Figure 3D).
Taken together, our data describes a mechanistic pathway 
leading to downregulation of the ABC transporters MDR-1 
and BCRP in drug-resistant MCF7 cells. We suggest the 
novel antagonistic interplay between TRG and PPARγ in 
drug-resistant MCF7 cells. Our data supports the possibility 
that PPARγ plays a role in MDR-1 and/or BCRP expression 
and is required for the drug-resistant phenotype. Further 
work is planned to investigate this possibility. Our work also 
demonstrates that TRG’s action on histone modiﬁ  cations and 
downregulation of ABC transporters may be tightly linked, 
as our experiments that alter histone modiﬁ  cations also affect 
MDR-1 and/or BCRP expression.
Discussion
In the present experiments we have shown that the devel-
opment of DOX resistance in both MCF7 and K562 cells 
following DOX-selection is associated with increased levels 
of the ABC transporters MDR-1 and BCRP. Expression of 
BCRP was previously demonstrated in a DOX-resistant 
MCF7 cell line.24 Exposure of MCF7/DOX and K562/DOX 
cells to TRG resulted in decreased levels of both MDR-1 
and BCRP. Furthermore, we show that following exposure 
to TRG, the DOX-selected cells again become susceptible 
to DOX treatment. This is similar to our previous observa-
tions showing DOX-selected K562 human leukemia cells 
exposed to both TRG and DOX were killed more readily.12 
In that study, TRG also downregulated GLO-1 expression in 
K562/DOX cells. Increased GLO-1 expression is thought to 
be associated with the MDR phenotype.10,11 Our combined 
ﬁ  ndings support the hypothesis that TRG induces multiple 
changes within MDR cells that lead to increased sensitivity 
to DOX once again.
TRG is more effective at downregulating MDR-1 than 
BCRP (Figure 1A). BCRP does not efﬂ  ux anthracyclines 
such as DOX unless there is a mutation within codon 482 of 
the BCRP gene.24 Thus, downregulation of MDR-1 gene 
expression likely accounts, in part, for how TRG overcomes 
DOX-resistance. Our data supports this hypothesis, as par-
tial silencing of MDR-1 using siRNA renders MCF7/DOX 
cells sensitive to DOX (Figure 2). Of interest is that the 
combination of TRG and DOX was much more effective 
at killing MCF7/DOX cells than in killing unselected 
MCF7 cells (Figure 1D). This may be due to a number of 
possible reasons. One we favor may be that in MCF7/DOX 
cells treated with TRG and DOX, DOX now accumulates 
because of the TRG-induced decreased expression of the 
ABC transporters. MDR cells display a wide range of 
alterations, including increased mutation to p53, reduced cell 
cycle checkpoint response and reduced apoptotic clearing 
of damaged cells.3 We have also found that TRG induces 
DNA damage (Davies and Harkness, unpublished data). 
The combination of increased DOX activity within these 
cells, and altered cell cycle control and cellular maintenance 
systems often observed in MDR cancer cells, suggests that 
MCF7/DOX cells cannot respond as effectively to DOX 
as unselected MCF7 cells. A second way that combination 
DOX + TRG acts to reverse DOX resistance may be due to 
selection of epigenetic changes that make them more vulner-
able to antiproliferative agents. We have previously shown 
that DOX-selected K562 cells have major changes in histone 
H3 acetylation and phosphorylation.12 DOX-resistant MCF7 
cells have also been shown to have major epigenetic changes 
including global decreases in DNA cytosine methylation, 
gene-speciﬁ  c hypo- or hypermethylation states as well as 
changes in histone acetylation and methylation states.25 Our 
unpublished work shows that TRG can inhibit the activity 
of histone acetyltransferases (HDACs) in treated cells, and 
more importantly, in treated cell lysates, which suggests 
that TRG is capable of binding HDAC enzymes to block 
their function.
There are at least two possible approaches in countering 
MDR. One is the development of compounds that interfere 
with the drug efﬂ  ux mechanism of the ABC transporters26 
and clinical trials on the most promising candidates have, so 
far, led to disappointing outcomes.27 A major problem with 
using transport inhibitors is their nonspeciﬁ  city for cancer 
cells. These efﬂ  ux pumps have been found, and have func-
tions, in a variety of tissues. Thus, for example, MDR-1 is 
strongly expressed in the adrenal gland, kidney and small 
intestine whereas BCRP is strongly expressed in tissues such 
as in liver and central nervous system:28 hence, inhibitors can 
affect normal physiological function. A second approach is to 
downregulate the expression of the drug efﬂ  ux pumps. One 
way to do this is by using molecular biology approaches, 
for example, delivery of siRNAs.29 How readily this can be 
translated into human clinical trials is not clear, as siRNA 
delivery must be selective for tumor cells, otherwise, normal 
physiological functions may be affected. In addition, the Drug Design, Development and Therapy 2009:3 86
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delivery vector should not give rise to ontoward effects. 
The use of a pharmacological approach to downregulate 
MDR-1 expression just prior to chemotherapy seems a 
more feasible approach. A number of compounds have 
been shown to partially decrease MDR-1 expression, these 
include honokiol (2-(4-hydroxy-3-prop-2-enyl-phenyl)-
4-prop-2-enyl-phenol), a biphenolic compound present in 
traditional Japanese medicines prepared from Magnolia 
grandiﬂ  oris30 and curcumin ((1E,6E)-1,7-bis(4-hydroxy-
3-methoxyphenyl)-1,6-heptadiene-3,5-dione), a biphenolic 
that is the major anticancer compound found in turmeric.31 
Recently the histone deacetylase inhibitors (HDACi’s) 
Trichostatin A (TSA) and sodium butyrate have been shown 
to downregulate MDR-1 expression in multidrug-resistant 
small cell lung carcinoma cell line.32 These data support 
our hypothesis that MDR-1 and BCRP downregulation by 
TRG involves inhibition of HDAC enzymes and epigenetic 
alterations at these promoters.
We took several approaches to examine possible 
mechanisms involved in MDR-1 and BCRP downregulation. 
First, we tested whether the DNA methylase inhibitor 
5-AzaC could also downregulate MDR-1 and/or BCRP 
in MCF7/DOX cells. We found that 5-AzaC could indeed 
downregulate both BCRP and MDR-1 in a dose-dependent 
manner (Figure 1C). This is in contrast to observations that 
5-AzaC treatment of human drug sensitive T cell leukemia 
cells resulted in hypomethylation of the MDR-1 promoter 
and activation of transcription.33 Similarly, in cultured human 
keratinocytes, 7.5 μM TRG induced transcription of the ABC 
transporter family member ABCA12, mutation of which is 
responsible for type 2 lamellar ichthyosis and Harlequin 
ichthyosis.34 The promoter of MDR-1 in DOX-resistant 
MCF7 was previously shown to harbor hypomethylated 
DNA and hyperacetylated histones, consistent with tran-
scriptional activation.35 Thus, downregulation of MDR-1 in 
MCF7/DOX by 5-AzaC in our experiments likely occurs via 
increased activity of a transcriptional repressor that acts at 
the MDR-1 promoter. Interestingly, a previous study of drug-
resistant K562 cells demonstrated that the repressor binding 
site within the MDR-1 promoter was methylated, blocking 
binding of a repressor.36 Treatment of these cells with 5-AzaC 
demethylated the repressor binding site, leading to down-
regulated transcription of MDR-1, a beneﬁ  cial outcome. 
Several proteins have been shown to repress MDR-1 expres-
sion, including the AML1/ETO and TEL/AML1 chimeric 
proteins found in acute lymphoblastic leukemia (ALL),37 
the pathogenic amino-terminal region of huntingtin (htt), 
httex1p,38 and c-Jun.39 The repression of MDR-1 expression 
by c-Jun is stimulated by a ubiquitin-protein ligase, Siah1, 
that conversely does not promote MDR-1 degradation, 
but rather, increases its transcriptional downregulation by 
promoting the binding of the c-Jun repressor to the AP1 
activator binding site in the MDR-1 promoter.40 The action 
of c-Jun likely plays a key role in mediating 5-AzaC, and 
perhaps TRG, down-regutation of at least MDR-1.
A second possible mechanism accounting for downregu-
lation of the ABC transporters could involve PPARγ. TRG is 
a known PPARγ ligand and has been shown in previous stud-
ies to act as a PPARγ agonist.17,18 Recently, many studies have 
indicated TRG may have “off-targets” that are not PPARγ 
dependent.19,20 Our studies show that use of the irreversible 
PPARγ inhibitor GW9662 in the nM range (5–20 nM) does 
not block TRG effects, but rather, accentuates them. For 
example, GW9662 increased histone H3K9 acetylation in 
TRG-treated parental MCF7 cells (Figure 3A); increased 
histone H3K79 monomethylation in untreated MCF7 parental 
cells (Figure 3B); and reduced expression of BCRP in MCF7/
DOX cells (Figure 3C). Increased histone modiﬁ  cations are 
observed in MCF7 (Davies and Harkness, unpublished data) 
and K562 cells12 when treated with TRG. Thus, PPARγ may 
be acting in an opposing fashion to TRG. A recent report 
found that GW9662 was a potent antiproliferative agent 
against hematopoietic and epithelial cancer cell lines and that 
these effects did not correlate with PPARγ protein levels.41 
It was concluded that GW9662 may have other mechanisms 
of action that may be PPARγ-independent. However, it is 
important to note that GW9662 in these studies was used 
in the μM range (5–25 μM), 1,000 × more concentrated 
than the concentrations used in our studies. Leesnitzer and 
colleagues21 showed that GW9662 inhibited PPARγ, PPARα, 
and PPARδ and with IC50s of 3.3 nM, 32 nM, and 2 μM, 
respectively. Furthermore, Leesnitzer and colleagues21 show 
that at 10 μM, GW9662 acted as an agonist for the nuclear 
receptors PXR and FXR. In the μM range GW9662 kills 
cells and shows action on multiple “off-targets”.21,41,42 In 
our studies presented here using GW9662 in the nM range, 
we do not observe killing, but do observe multiple effects 
at the histone and BCRP protein level. Nonetheless, recent 
literature implicates PPARγ as an antiproliferative agent, not 
one involved in promoting an MDR phenotype.43–45 Thus, 
additional work must be conducted to determine whether 
the effects of GW9662 in our study implicate PPARγ as a 
mediator of MDR.
Recently we observed that TRG killing of cancer 
cells is associated with decreased AKT phosphorylation 
(Davies and Harkness, unpublished data). Treatment of MCF7 Drug Design, Development and Therapy 2009:3 87
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cells with the PI3 kinase inhibitor LY294002, but not the ERK 
inhibitor PD98059, resulted in increased H3K9 acetylation, 
similar to TRG and trichostatin A treatment. Here, we show 
that LY294002, and not PD98059, downregulated BCRP 
expression (Figure 3D). The status of TRG and its action on 
AKT signaling is currently controversial, as recent reports 
show that TRG either plays or does not play a role in AKT 
function.46–50 Our data support the idea that AKT signaling 
plays a role in the MDR phenotype.
Of the experimental approaches that have shown to down-
regulate MDR, TRG has the major advantage in that there 
is extensive clinical experience using TRG as an insulin-
sensitizing agent for treatment of type 2 diabetes.51 TRG 
was withdrawn from the market because chronic treatment 
resulted in a small subset of patients (2%) experiencing 
severe liver dysfunction that occasionally led to death due to 
liver failure (1:100,000 patients monitored; Scheen, 2001).52 
However, if TRG were to be used as an adjunct therapy it 
would be given for only a few days before a chemotherapy 
session. Under such acute use one would not anticipate a 
similar occurrence of liver dysfunction observed with chronic 
TRG use.
Based upon an extensive literature demonstrating that 
TRG inhibits tumor growth in vitro and in animal models,53,54 
human clinical trials were initiated where TRG was used as 
the sole chemotherapeutic agent. Unfortunately, these clinical 
trials have yielded disappointing results.55,56 Our data suggest 
that by downregulating expression of MDR-1 and BCRP 
in DOX-resistant cells, TRG ought to be a useful adjunct 
therapy in combination with a standard chemotherapy.
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